Stock Price of Immunomedics, Inc. (IMMU) Increases 18.86%

Immunomedics, Inc.s in-depth stock price analysis indicates that the stock price has rallied 66.03% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 92.28% . Looking at the past 52 week period, the stock price is up at 153.88% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Immunomedics, Inc. has a positive value of 46.8 compared to overall market. Immunomedics, Inc. (NASDAQ:IMMU) has climbed 18.86% in the past week and advanced 29.46% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 17.91% and the outperformance has advanced to 27.14% for the last 4 weeks period.

Immunomedics, Inc. (NASDAQ:IMMU) : On Friday heightened volatility was witnessed in Immunomedics, Inc. (NASDAQ:IMMU) which led to swings in the share price. The stock opened for trading at $4.64 and hit $5.89 on the upside , eventually ending the session at $5.23, with a gain of 21.63% or 0.93 points. The heightened volatility saw the trading volume jump to 54,348,196 shares. The 52-week high of the share price is $5.89 and the company has a market cap of $555 million. The 52-week low of the share price is at $1.87 .

Company has reported several Insider transactions to the SEC, on Aug 25, 2016, Brian A Markison (director) sold 15,000 shares at 2.98 per share price.On Aug 25, 2016, Don C Stark (director) sold 9,900 shares at 2.97 per share price.On Aug 25, 2016, Mary E Paetzold (director) sold 15,000 shares at 2.98 per share price.

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.


Share this post

Leave a Reply